WO2011122899A3 - Pharmaceutical composition for inhibiting platelet aggregation or for thrombolysis - Google Patents

Pharmaceutical composition for inhibiting platelet aggregation or for thrombolysis Download PDF

Info

Publication number
WO2011122899A3
WO2011122899A3 PCT/KR2011/002267 KR2011002267W WO2011122899A3 WO 2011122899 A3 WO2011122899 A3 WO 2011122899A3 KR 2011002267 W KR2011002267 W KR 2011002267W WO 2011122899 A3 WO2011122899 A3 WO 2011122899A3
Authority
WO
WIPO (PCT)
Prior art keywords
platelet aggregation
thrombolysis
inhibiting platelet
pharmaceutical composition
present
Prior art date
Application number
PCT/KR2011/002267
Other languages
French (fr)
Korean (ko)
Other versions
WO2011122899A2 (en
Inventor
곽수종
정춘식
권순경
Original Assignee
Kwak Soo Jong
Jeong Choon Sik
Kwon Soon Kyoung
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kwak Soo Jong, Jeong Choon Sik, Kwon Soon Kyoung filed Critical Kwak Soo Jong
Publication of WO2011122899A2 publication Critical patent/WO2011122899A2/en
Publication of WO2011122899A3 publication Critical patent/WO2011122899A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Abstract

The present invention relates to a pharmaceutical composition for inhibiting platelet aggregation or for thrombolysis. The present invention relates to a composition which has superior effectiveness and fewer side effects than conventional well-known pharmaceutical compositions for inhibiting platelet aggregation or for thrombolysis. The pharmaceutical composition for inhibiting platelet aggregation or for thrombolysis, according to the present invention, comprises ibudilast and triflusal as active ingredients due to the fact that ibudilast and triflusal have superior effectiveness in inhibiting platelet aggregation and thus exhibit synergistic effects and reduce the risk of bleeding when co-administered, as compared to respectively administering ibudilast and triflusal alone. The pharmaceutical composition of the present invention can be used in the prevention or treatment of various diseases and symptoms, for example, ischemic heart disease, ischemic cerebral infarction, arteriosclerosis, and thrombosis caused by the insertion of a stent, etc.
PCT/KR2011/002267 2010-04-01 2011-04-01 Pharmaceutical composition for inhibiting platelet aggregation or for thrombolysis WO2011122899A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020100029980A KR101169449B1 (en) 2010-04-01 2010-04-01 Pharmaceutical composition for inhibiting platelet aggregation or for thrombolysis
KR10-2010-0029980 2010-04-01

Publications (2)

Publication Number Publication Date
WO2011122899A2 WO2011122899A2 (en) 2011-10-06
WO2011122899A3 true WO2011122899A3 (en) 2012-02-02

Family

ID=44712791

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2011/002267 WO2011122899A2 (en) 2010-04-01 2011-04-01 Pharmaceutical composition for inhibiting platelet aggregation or for thrombolysis

Country Status (2)

Country Link
KR (1) KR101169449B1 (en)
WO (1) WO2011122899A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015030543A1 (en) * 2013-08-30 2015-03-05 한국한의학연구원 Composition containing mulberry leaf alcohol extract as active ingredient for preventing and treating thrombotic diseases
CN108703971B (en) * 2017-07-11 2023-04-07 南华大学 Application of anti-HIV (human immunodeficiency virus) medicament, namely, cobicistat, in preparation of antithrombotic medicament
WO2021061554A1 (en) * 2019-09-23 2021-04-01 Medicinova, Inc. Ibudilast oral formulations and methods of using same

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050187278A1 (en) * 2003-08-28 2005-08-25 Pharmacia Corporation Treatment or prevention of vascular disorders with Cox-2 inhibitors in combination with cyclic AMP-specific phosphodiesterase inhibitors

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050187278A1 (en) * 2003-08-28 2005-08-25 Pharmacia Corporation Treatment or prevention of vascular disorders with Cox-2 inhibitors in combination with cyclic AMP-specific phosphodiesterase inhibitors

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ANNINOS, H. ET AL.: "Triflusal: An Old Drug in Modern Antiplatelet Therapy. review of Its action, Use, Safety and Effectiveness", HELLENIC JOURNAL OF CARDIOLOGY, vol. 50, May 2009 (2009-05-01), pages 199 - 207 *
RILE, G. ET AL.: "Potentiation of Ibudilast Inhibition of Platelet Aggregation in the Prescence of Endothelial Cells", THROMBOSIS RESEARCH, vol. 102, 2001, pages 239 - 246 *

Also Published As

Publication number Publication date
WO2011122899A2 (en) 2011-10-06
KR101169449B1 (en) 2012-07-30
KR20110110582A (en) 2011-10-07

Similar Documents

Publication Publication Date Title
PH12017501079A1 (en) 1,3-thiazol-2-yl substituted benzamides
WO2009039460A3 (en) Co-administration of pimavanserin with other agents
WO2017022962A8 (en) Composition for preventing or treating immune disease, comprising ripk inhibitor as active ingredient
WO2013066839A3 (en) Compounds and methods
WO2013066835A3 (en) Compounds and methods
TN2017000467A1 (en) Amido-substituted cyclohexane derivatives
AR088195A1 (en) PHARMACEUTICAL COMPOSITIONS OF N-METHYL-2- [3- (E) -2-PIRIDIN-2-IL-VINIL) -1H-INDAZOL-6-ILSULFANIL] -BENZAMIDA
WO2010005480A3 (en) Controlled release compositions of agents that reduce circulating levels of platelets and methods therefor
MY168413A (en) Amino-substituted imidazopyridazines
WO2012094598A3 (en) Pharmaceutical compositions of iron for oral administration
ECSP14033371A (en) PHARMACEUTICAL COMPOSITIONS AND TREATMENT OF MASTITIS
WO2014131739A3 (en) Substituted imidazopyridazines
WO2014147182A3 (en) Substituted n-biphenyl-3-acetylamino-benzamides and n-[3-(acetylamino)phenyl]-biphenyl-carboxamides and their use as inhibitors of the wnt signalling pathway
WO2015150449A3 (en) Amido-substituted azole compounds as inhibitors of tnks1 and/or tnks2
PH12019501424A1 (en) Carboxylic acid aromatic amides as antagonists of bradykinin b1 receptor
NZ702705A (en) Pharmaceutical composition containing verbenone derivative for treating or preventing neurodegenerative disease
WO2011122899A3 (en) Pharmaceutical composition for inhibiting platelet aggregation or for thrombolysis
PH12016501814A1 (en) Inhibitors of the wnt signalling pathways
WO2014071168A3 (en) Administering inhibitors of tgfbeta signaling to improve muscle function in cancer patients
WO2012064159A3 (en) Anticancer composition
WO2012106058A3 (en) Animal treatments
WO2013000895A9 (en) Dha and epa in the reduction of oxidative stress
WO2014047288A3 (en) Transglutaminase tg2 inhibitors, pharmaceutical compositions, and methods of use thereof
WO2010142400A3 (en) Chitosan oligosaccharide-based compositions
WO2016032127A3 (en) Novel compounds having antioxidant and anti-inflammatory activities due to competition with lps for binding to tlr4, and medical use thereof

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11763071

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 11763071

Country of ref document: EP

Kind code of ref document: A2